Quick Answer
ESCALON MEDICAL CORP reported Total Revenue of $9.40 million for fiscal year 2020.
ESCALON MEDICAL CORP — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | $9.40M -2.4% |
| Net Income | $105.5K +184.2% |
-$125.3K -127.4% |
$456.8K +2426.6% |
$18.1K +134.8% |
-$52.0K +92.0% |
-$650.3K -160.1% |
| Diluted EPS | $0.00 +100.0% |
-$0.02 -166.7% |
$0.03 | $0.00 +100.0% |
-$0.01 +88.9% |
-$0.09 -125.0% |
| Total Assets | $4.99M +4.9% |
$4.76M -10.4% |
$5.31M +2.6% |
$5.17M -9.0% |
$5.68M -0.7% |
$5.72M +11.6% |
| Cash and Equivalents | $545.8K +161.1% |
$209.0K -76.5% |
$889.7K +49.8% |
$593.9K -64.0% |
$1.65M +99.9% |
$826.0K +101.6% |
| Long-Term Debt | — | — | — | — | — | — |
| Stockholders Equity | $1.92M +5.8% |
$1.81M -6.5% |
$1.93M +30.9% |
$1.48M +1.2% |
$1.46M -3.4% |
$1.51M -30.1% |
| R&D Expense | $753.1K +9.4% |
$688.2K -15.9% |
$818.8K -17.4% |
$991.0K +11.3% |
$890.5K -20.7% |
$1.12M +51.7% |
| Operating Income | $133.2K +227.5% |
-$104.5K -121.8% |
$478.5K +201.8% |
-$470.1K -1295.0% |
-$33.7K +97.6% |
-$1.40M -453.3% |
| Shares Outstanding | 7.42M +0.0% |
7.42M +0.0% |
7.42M +0.0% |
7.42M +0.0% |
7.42M +0.0% |
7.42M +0.0% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | March 31, 2025 | $3.47M | +28.9% | +7.9% |
| Revenue (ASC 606) | March 31, 2025 | $3.47M | +28.9% | +7.9% |
| Net Income | December 31, 2025 | $97.7K | -60.3% | +140.7% |
| Diluted EPS | December 31, 2025 | $0.01 | -50.0% | +133.3% |
| Total Assets | June 30, 2026 | $4.69M | -6.1% | -5.9% |
| Cash and Equivalents | December 31, 2025 | $337.4K | -35.2% | -45.2% |
| Long-Term Debt | March 31, 2018 | $18.9K | — | — |
| Stockholders Equity | December 31, 2025 | $1.77M | -12.4% | +5.8% |
| R&D Expense | December 31, 2025 | $131.2K | -15.9% | -39.3% |
| Operating Income | December 31, 2025 | $98.7K | -61.4% | +148.7% |
| Shares Outstanding | June 30, 2026 | 7.42M | +0.0% | +0.0% |
- ESCALON MEDICAL CORP reported Total Revenue of $9.40 million for fiscal year 2020.
- ESCALON MEDICAL CORP showed a decrease of -2.4% in Total Revenue compared to the prior fiscal year.
- ESCALON MEDICAL CORP reported Net Income of $105.5 thousand for fiscal year 2025.
- ESCALON MEDICAL CORP showed an increase of +184.2% in Net Income compared to the prior fiscal year.
- ESCALON MEDICAL CORP reported Diluted EPS of $0.00 per share for fiscal year 2025.
- ESCALON MEDICAL CORP showed an increase of +100.0% in Diluted EPS compared to the prior fiscal year.
- ESCALON MEDICAL CORP reported Total Assets of $4.99 million for fiscal year 2025.
- ESCALON MEDICAL CORP showed an increase of +4.9% in Total Assets compared to the prior fiscal year.
- ESCALON MEDICAL CORP reported Cash and Equivalents of $545.8 thousand for fiscal year 2025.
- ESCALON MEDICAL CORP showed an increase of +161.1% in Cash and Equivalents compared to the prior fiscal year.
- ESCALON MEDICAL CORP reported Long-Term Debt of $0.00 for fiscal year 2012.
- ESCALON MEDICAL CORP showed a decrease of -100.0% in Long-Term Debt compared to the prior fiscal year.
- ESCALON MEDICAL CORP reported Stockholders Equity of $1.92 million for fiscal year 2025.
- ESCALON MEDICAL CORP showed an increase of +5.8% in Stockholders Equity compared to the prior fiscal year.
- ESCALON MEDICAL CORP reported R&D Expense of $753.1 thousand for fiscal year 2025.
- ESCALON MEDICAL CORP showed an increase of +9.4% in R&D Expense compared to the prior fiscal year.
- ESCALON MEDICAL CORP reported Operating Income of $133.2 thousand for fiscal year 2025.
- ESCALON MEDICAL CORP showed an increase of +227.5% in Operating Income compared to the prior fiscal year.
- ESCALON MEDICAL CORP reported Shares Outstanding of 7.42 million shares for fiscal year 2025.
- ESCALON MEDICAL CORP showed an increase of +0.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: